As COVID cases rise, U.S. health officials mull widening additional booster eligibility
Reuters
Published May 18, 2022 12:21PM ET
Updated May 18, 2022 03:11PM ET
By Ahmed Aboulenein and Jeff Mason
WASHINGTON (Reuters) - Health officials are considering extending the eligibility for a second COVID-19 vaccine booster dose to people under 50 amid a steady rise in cases, with the United States seeing a threefold increase over the past month.
The U.S. Food and Drug Administration had in late March authorized a second booster dose of the Moderna (NASDAQ:MRNA) and Pfizer/BioNTech SE vaccines for people aged 50 and older, citing data showing waning immunity and the risks posed by Omicron variants of the virus.
"With regard to a fourth dose for those under the age of 50, that is going to require action from the FDA, and we're in conversations there," U.S. Centers for Disease Control and Prevention Director Rochelle Walenksy said on Wednesday.
Cases have steadily risen over the past five weeks, Walensky said at a White House briefing, with the the current seven-day average of daily cases rising 26% from the previous week to 94,000 cases per day and up threefold over the last month. The seven-day average for hospitalizations was up 19% to about 3,000 per day and the average for deaths was 275 per day, she said.
"We of course must remember that each person lost to COVID-19 is a tragedy and that nearly 300 deaths a day is still far too many," said Walensky.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.